Aripiprazole Tablet
Product Images NDC 27241-051

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Aripiprazole (NDC 27241-051). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Ajanta Pharma Usa Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Aripiprazole Fig4

A graph titled 'Aripiprazole Fold Change and 90% CI' showing the pharmacokinetic (PK) parameters AUC and Cmax across special populations, including CYP2D6 metabolizer status, gender, age, hepatic impairment levels, and severe renal impairment. The x-axis represents change relative to reference values on a scale from 0.5 to 3.0 with data points indicating fold changes and confidence intervals.*

FDA Label Image

Aripiprazole Fig5

A forest plot showing the fold change and 90% confidence intervals for Dehydro-Aripiprazole pharmacokinetics. The chart compares AUC and Cmax values relative to reference across categories such as CYP2D6 metabolizer status, gender, age groups, hepatic impairment severity, and severe renal impairment.*

FDA Label Image

Structure (Aripiprazole Struct)

Chemical structure of Aripiprazole, showing its molecular arrangement including chlorine atoms, piperazine ring, and quinolinone moiety, consistent with the active ingredient in Aripiprazole tablets.*

FDA Label Image

Aripiprazole10mg

Packaging label for Aripiprazole Tablets, USP 10 mg, supplied by Ajanta Pharma USA Inc. The label indicates 30 tablets per bottle with child-resistant packaging. Storage instructions specify 25°C (77°F) with permitted excursions. The label includes the NDC 27241-053-03 and a barcode, with dispensing instructions for pharmacists to provide the enclosed Medication Guide.*

FDA Label Image

Aripiprazole15mg

Label for Aripiprazole Tablets USP 15 mg, oral tablets in a 30-count package. The label includes storage instructions, manufacturer details (Ajanta Pharma USA Inc., made in India), the NDC code 27241-054-03, and a barcode. It also notes the package is child-resistant and for prescription use only.*

FDA Label Image

Aripiprazole20mg

Label for Aripiprazole Tablets, USP 20 mg oral tablets by Ajanta Pharma USA Inc. The label states a 30-tablet package with NDC 27241-055-03. It includes storage instructions, a child-resistant warning, and a pharmacist's dispensing note. The label features the Ajanta logo and a barcode.*

FDA Label Image

Aripiprazole2mg

Aripiprazole Tablets USP 2 mg oral tablets packaging label for a bottle containing 30 tablets. The label includes storage instructions, child-resistant packaging note, and the marketer Ajanta Pharma USA Inc. The label features a barcode, NDC 27241-051-03, and a designated unvarnished area for lot and expiration information.*

FDA Label Image

Aripiprazole30mg

Packaging label for Aripiprazole Tablets USP, 30 mg strength, containing 30 tablets. The label includes the NDC number 27241-056-03 and states the product is marketed by Ajanta Pharma USA Inc. Storage instructions specify keeping the product at 25°C with allowed temperature excursions. The label also contains a pharmacist instruction to dispense the enclosed Medication Guide and a barcode.*

FDA Label Image

Aripiprazole5mg

Label for Aripiprazole Tablets, USP 5 mg with a package containing 30 tablets. The label includes the National Drug Code (NDC) 27241-052-03 and indicates the product is marketed by Ajanta Pharma USA Inc. It instructs pharmacists to dispense the enclosed Medication Guide, notes the packaging is child-resistant, and provides storage conditions. The label features a barcode and a designated area for lot and expiration dates.*

FDA Label Image

Aripiprazole_fig_01 (Aripiprazole Fig 01)

A scatter plot chart titled 'Effect of Other Drugs on Aripiprazole' showing Aripiprazole fold change and 90% confidence intervals for various interacting drugs. The x-axis shows change relative to reference without interacting drug, ranging from 0.5 to 3.0, and the y-axis lists drug types categorized as CYP3A4 inhibitors, CYP2D6 inhibitors, CYP3A4 inducers, gastric acid blockers, and others with corresponding pharmacokinetic parameters AUC and Cmax.*

FDA Label Image

Aripiprazole_fig_02 (Aripiprazole Fig 02)

A chart showing the effect of various drugs on Aripiprazole pharmacokinetics, specifically the dehydro-aripiprazole fold change and 90% confidence intervals for AUC and Cmax values. Drugs listed include CYP3A4 inhibitors and inducers, CYP2D6 inhibitor, gastric acid blockers, and others, with changes relative to a reference without interacting drug plotted on the x-axis.*

FDA Label Image

Aripiprazole_fig_03 (Aripiprazole Fig 03)

A forest plot chart showing the effect of Aripiprazole on the pharmacokinetics of various drugs, including dextromethorphan, warfarin (S- and R-), omeprazole, lamotrigine, valproate, lithium, lorazepam, venlafaxine, O-desmethylvenlafaxine, and escitalopram. The chart illustrates fold change and 90% confidence intervals for parameters like AUC and Cmax compared to reference values without interacting drugs.*

FDA Label Image

Figure6 (Aripiprazole Fig 06)

A Kaplan-Meier survival curve chart comparing the proportion of subjects experiencing relapse over time between Aripiprazole and placebo groups. The horizontal axis shows days since randomization, and the vertical axis indicates the proportion with relapse. Numbers of subjects at risk are listed below the time axis for each group.*

FDA Label Image

Aripiprazole_fig_07 (Aripiprazole Fig 07)

A Kaplan-Meier survival curve comparing the proportion of subjects with relapse over days from randomization between Aripiprazole and placebo groups. The x-axis represents days from randomization, and the y-axis shows the proportion with relapse. The number of subjects at risk at various time points is listed below the x-axis for both treatments.*

FDA Label Image

Aripiprazole_fig_08 (Aripiprazole Fig 08)

A Kaplan-Meier curve graph comparing the proportion with relapse over days from randomization between two groups: Aripiprazole and Placebo. The x-axis represents days from randomization, and the y-axis represents the proportion with relapse. Sample sizes at risk at various time points are shown below the x-axis for both groups.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.